Currently, a phase III trial (FIGHT: NCT03694522) is ongoing to evaluate 1L use of the FGFR2b inhibitor bemarituzumab in FGFR2b-overexpressing GC, as determined by IHC assay, or in FGFR2-amplified GC, as detected using ctDNA analysis. The gene discussed is FGFR2; the disease is gastric cancer.